Simple Summary This review article addresses the toxic effects on the heart associated with
the use of certain cancer-treating drugs known as immune checkpoint inhibitors. These …

Myocarditis associated with the use of immune checkpoint inhibitors (ICI) is a rare
manifestation of their cardiotoxicity, but is characterized by a high mortality rate. A literature …

Immune checkpoint inhibitors (ICIs) are an important advancement in the field of cancer
treatment, significantly improving the survival of patients with a series of advanced …

Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events
including myocarditis, whilst improving cancer-related outcomes. There is thus a clinical …

Background Immune checkpoint inhibitors (ICIs) therapy can be complicated by their
potential cardiovascular toxicities, including myocarditis. Nowadays, no prospective trials …

Immune checkpoint inhibitor (ICI) therapy has played an important role in the treatment of
several groups of cancers. Although a life prolonging treatment, many side effects have …

Introduction Camrelizumab is an antibody against programmed death protein 1 (PD-1) and
is one of immune checkpoint inhibitors (ICI). ICI may lead to autoimmune myocarditis, which …

The emerging use of immunotherapies in cancer treatment increases the risk of
immunotherapy-related cardiotoxicity. In contrast to conventional chemotherapy, these novel …

Introduction Immune checkpoint inhibitors can cause immune-related toxicity in various
systems, with myocarditis being the most severe and life-threatening manifestation. This …

Immunoterapia przeciwnowotworowa to nowa, obiecująca metoda leczenia, wykorzystująca
naturalny system odpornościowy organizmu. Dzieli się na terapię aktywną i bierną …